Leerink downgraded AlloVir to Market Perform from Outperform with a price target of $1, down from $14, after the company announced discontinuation of its three Phase 3 studies for lead asset posoleucel based on pre-planned futility analyses by the Data Safety Monitoring Boards, or DSMBs, that indicated the studies were unlikely to meet their primary endpoints. Given the news, the firm expects the shares to trade near cash value net of projected operating expenses while investors await the outcomes of the ongoing strategic review.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALVR:
- AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
- AlloVir reports Q3 EPS (39c), consensus (42c)
- ALVR Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue